PRAX - Praxis Precision Medicines  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

PRAX is currently covered by 8 analysts with an average price target of $71.24. This is a potential upside of $33.89 (90.74%) from yesterday's end of day stock price of $37.35.

Praxis Precision Medicines 's activity chart (see below) currently has 13 price targets and 55 ratings on display. The stock rating distribution of PRAX is 78.05% BUY, 19.51% HOLD and 2.44% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 28.75% with an average time for these price targets to be met of 35.88 days.

Highest price target for PRAX is $170, Lowest price target is $28, average price target is $109.2.

Most recent stock forecast was given by LAURA CHICO from WEDBUSH on 05-May-2025. First documented stock forecast 11-Nov-2020.

Currently out of the existing stock ratings of PRAX, 32 are a BUY (78.05%), 8 are a HOLD (19.51%), 1 are a SELL (2.44%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

$28

$-9.02 (-24.37%)

$51

14 days ago
(05-May-2025)

12/15 (80%)

$-10.96 (-28.13%)

134

Buy

$80

$42.98 (116.10%)

$85

14 days ago
(05-May-2025)

0/8 (0%)

$41.04 (105.34%)

Buy

$105

$67.98 (183.63%)

$105

18 days ago
(01-May-2025)

0/12 (0%)

$66.94 (175.88%)

Buy

$163

$125.98 (340.30%)

$143

6 months 18 days ago
(31-Oct-2024)

0/4 (0%)

$93.01 (132.89%)

Buy

$170

$132.98 (359.21%)

$155

9 months 5 days ago
(14-Aug-2024)

0/2 (0%)

$118.74 (231.64%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is PRAX (Praxis Precision Medicines ) average time for price targets to be met?

On average it took 35.88 days on average for the stock forecasts to be realized with a an average price target met ratio 28.75

Which analyst has the current highest performing score on PRAX (Praxis Precision Medicines ) with a proven track record?

LAURA CHICO

Which analyst has the current lower performing score on PRAX (Praxis Precision Medicines ) with a proven track record?

YATIN SUNEJA

Which analyst has the most public recommendations on PRAX (Praxis Precision Medicines )?

Laura Chico works at WEDBUSH and has 22 price targets and 12 ratings on PRAX

Which analyst is the currently most bullish on PRAX (Praxis Precision Medicines )?

Yatin Suneja with highest potential upside - $132.98

Which analyst is the currently most reserved on PRAX (Praxis Precision Medicines )?

Tazeen Ahmad with lowest potential downside - -$86.27

Praxis Precision Medicines  in the News

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 02, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit...

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen Vormatrigine continues to generate a best-in-class safety profile with new data...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?